BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 2, 2024
See today's BioWorld
Home
» Array, Novartis Strike MEK Inhibitor Deal Worth up to $467M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Array, Novartis Strike MEK Inhibitor Deal Worth up to $467M
April 21, 2010
By
Catherine Hollingsworth
No Comments
Array BioPharma Inc. has snagged another oncology deal involving its MEK inhibitors, this time with Novartis AG in a collaboration that will bring in $45 million up front plus $422 million in milestones. (BioWorld Today)
BioWorld